2016-11-01
Decreased somatic hypermutation induces an impaired peripheral B cell tolerance checkpoint
Publication
Publication
Journal of Clinical Investigation , Volume 126 - Issue 11 p. 4289- 4302
Patients with mutations in AICDA, which encodes activation-induced cytidine deaminase (AID), display an impaired peripheral B cell tolerance. AID mediates class-switch recombination (CSR) and somatic hypermutation (SHM) in B cells, but the mechanism by which AID prevents the accumulation of autoreactive B cells in blood is unclear. Here, we analyzed B cell tolerance in AID-deficient patients, patients with autosomal dominant AID mutations (AD-AID), asymptomatic AICDA heterozygotes (AID+/-), and patients with uracil N-glycosylase (UNG) deficiency, which impairs CSR but not SHM. The low frequency of autoreactive mature naive B cells in UNG-deficient patients resembled that of healthy subjects, revealing that impaired CSR does not interfere with the peripheral B cell tolerance checkpoint. In contrast, we observed decreased frequencies of SHM in memory B cells from AD-AID patients and AID+/- subjects, who were unable to prevent the accumulation of autoreactive mature naive B cells. In addition, the individuals with AICDA mutations, but not UNGdeficient patients, displayed Tregs with defective suppressive capacity that correlated with increases in circulating T follicular helper cells and enhanced cytokine production. We conclude that SHM, but not CSR, regulates peripheral B cell tolerance through the production of mutated antibodies that clear antigens and prevent sustained interleukin secretions that interfere with Treg function.
Additional Metadata | |
---|---|
doi.org/10.1172/JCI84645, hdl.handle.net/1765/94295 | |
Journal of Clinical Investigation | |
Organisation | Department of Immunology |
Cantaert, T., Schickel, J.-N., Bannock, J.M. (Jason M.), Ng, Y.-S. (Yen-Shing), Massad, C. (Christopher), Delmotte, F.R. (Fabien R.), … Meffre, E. (2016). Decreased somatic hypermutation induces an impaired peripheral B cell tolerance checkpoint. Journal of Clinical Investigation, 126(11), 4289–4302. doi:10.1172/JCI84645 |